Paging Dr. Goldfarb

Article

Carrie Corey

My cancer center is also a teaching hospital, which means I often encounter the future of cancer treatment: oncologists in training. They usually enter the room before my doctor and ask about my diagnosis, symptoms and drug side effects. I visit my oncologist enough for him to know the answers to their questions, but the exercise helps teach them good bedside manner. I met my first oncology fellow soon after hearing the "C" word for the first time; so understandably, I was more than a little overwhelmed. The one thing my husband and I remembered from the discussion was that his name was Dr. Goldfarb, so from that moment on, every doctor-in-training I have met is simply referred to as a "Goldfarb." Now that I am a veteran in the cancer center, I have a hidden agenda when I meet a Goldfarb: I want to show them I am a person, not a textbook statistic. The ability to see patients as people instead of cancer cases is a valuable skill for an oncologist – one that will no doubt be appreciated by the thousands of patients a doctor will treat throughout his or her career. I tell them all how I was diagnosed with breast cancer at 29 with no strong family history. Thank goodness my gynecologist advocated for a biopsy even though the mammogram and ultrasound said my lump didn't have the characteristics of cancer. Statistically-speaking, it shouldn't have been cancer...but it was. My initial treatment included a double mastectomy with six hearty rounds of chemo. Statistically, I wasn't likely to have a recurrence...but I did. These are good lessons for anyone to learn, particularly doctors who will be diagnosing future cancer patients. Last year, I met a Goldfarb in my breast oncologist's office one week and saw him in the gynecological oncologist's office the following week. Upon our second introduction, I laughed, "We actually met last week. Looks like we get to talk about the north AND south poles!" He just stared at the floor and avoided eye contact – I guess the humor of the situation was lost on him.While most Goldfarbs take the opportunity to learn from patients, my most recent Goldfarb visit was extremely unsettling. I was telling him how it took almost six months to diagnose my recurrence because my X-rays were clean, despite a persistent cough and severe shoulder pain. He replied, "Well, statistics show that finding metastatic recurrence earlier doesn't mean you'll live any longer."WOW! In the four years since my first diagnosis, I have never felt more like a cancer statistic than I did at that moment. I'm not sure if Goldfarb was trying to sound knowledgeable, or if he is arrogant enough to believe we know everything about this wacky disease. Cancer is so individualized, we don't always know why a drug will work in one case and not another – a fact that is scary and encouraging at the same time.I quipped back, "Well, I have metastases to the lungs, liver and bones. Had we found my recurrence earlier, perhaps it would just be in my bones. And if I hadn't had so many spots by the time we discovered it, maybe I wouldn't have just spent 10 grueling months getting weekly chemo!"My husband likes to say that I play in the small percentages, and I tend to agree. I was in the small percentage of women diagnosed in her 20s. I am in the small percentage of women who are metastatic in her 30s. And I hope to be in the lucky percentage of women that dies of something other than cancer well into my 90s.We are not cancer statistics – we are people! I don't care how long the average woman lives with metastatic breast cancer, because frankly – who wants to settle for being average?Carrie Corey is a wife, mom and metastatic breast cancer survivor. She will be reporting in frequently on her journey.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content